Log In
Print
BCIQ
Print
Print this Print this
 

Savolitinib, volitinib (AZD6094, HMPL-504)

  Manage Alerts
Collapse Summary General Information
Company Hutchison China MediTech Ltd.
DescriptionInhibitor of c-Met receptor tyrosine kinase
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)
Mechanism of Actionc-Met receptor tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$140.0M

$20.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today